Drug Discovery: Genomic and Transcriptomic Approaches

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3063

Special Issue Editor


E-Mail Website1 Website2
Guest Editor
Department of Neurology, Jinan University, Guangzhou, China
Interests: bioinformatics; omics; drug discovery

Special Issue Information

Dear Colleagues,

With the development of sequencing capability and bioinformatics analytic tools, omics have become an indispensable tool in modern drug discovery. High-throughput data such as genomic, epigenetic, transcriptomic, proteomic, metabolomic, and ribosome profiling data as well as single-cell sequencing have all made significant contributions to mechanism-based drug discovery and drug repurposing. Omics data analysis can not only accelerate drug target identification and drug candidate screening but can also facilitate the characterization of side effects and predict drug resistance.

For this Special Issue, we encourage the use of omics data for drug-discovery-related exploration, aiming to provide a forum for advances in the development and application of omics-based drug-discovery strategies.

Original research articles and reviews that focus on, but are not limited to, the following topics are welcome:

  • The identification or verification of drug targets and biomarkers by integrating diverse omics data;
  • The identification of disease-associated screenable phenotypes based on omics data analysis;
  • The prediction or refinement of drug candidates through omics data mining;
  • Assessment of the potential for drug resistance or adverse drug reactions using omics data;
  • Prediction of a drug's activity, toxicity, or mechanism of action through omics data analysis. 

Prof. Dr. Keshen Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • omics
  • bioinformatics
  • drug discovery
  • drug response
  • drug target

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 10547 KiB  
Article
Repurposing Approved Drugs for Sarcopenia Based on Transcriptomics Data in Humans
by Shuang Liang, Danyang Liu, Zhengwu Xiao, Jonathan Greenbaum, Hui Shen, Hongmei Xiao and Hongwen Deng
Pharmaceuticals 2023, 16(4), 607; https://doi.org/10.3390/ph16040607 - 18 Apr 2023
Cited by 4 | Viewed by 2700
Abstract
Sarcopenia, characterized by age-related loss of muscle mass, strength, and decreased physical performance, is a growing public health challenge amid the rapidly ageing population. As there are no approved drugs that target sarcopenia, it has become increasingly urgent to identify promising pharmacological interventions. [...] Read more.
Sarcopenia, characterized by age-related loss of muscle mass, strength, and decreased physical performance, is a growing public health challenge amid the rapidly ageing population. As there are no approved drugs that target sarcopenia, it has become increasingly urgent to identify promising pharmacological interventions. In this study, we conducted an integrative drug repurposing analysis utilizing three distinct approaches. Firstly, we analyzed skeletal muscle transcriptomic sequencing data in humans and mice using gene differential expression analysis, weighted gene co-expression analysis, and gene set enrichment analysis. Subsequently, we employed gene expression profile similarity assessment, hub gene expression reversal, and disease-related pathway enrichment to identify and repurpose candidate drugs, followed by the integration of findings with rank aggregation algorithms. Vorinostat, the top-ranking drug, was also validated in an in vitro study, which demonstrated its efficacy in promoting muscle fiber formation. Although still requiring further validation in animal models and human clinical trials, these results suggest a promising drug repurposing prospect in the treatment and prevention of sarcopenia. Full article
(This article belongs to the Special Issue Drug Discovery: Genomic and Transcriptomic Approaches)
Show Figures

Figure 1

Back to TopTop